Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of ISM5411 in Healthy Subjects
NCT06012578Phase 1Completed
- Sponsor
- Insilico Medicine
- Start
- Nov 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in inflammatory bowel disease (IBD) and ulcerative colitis (UC) comparing ISM5411 with Placebo (2 arms). Primary endpoints: Number of participants with Adverse Events (AEs), Number of participants with clinically significant changes in vital signs and 3 more. Started Nov 2023; status: completed.
02
Drugs
garutadustat
03
Conditions
inflammatory bowel disease (IBD)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06012578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06012578.